कंपनी का अवलोकन
60 Degrees Pharmaceuticals, Inc. is a specialized pharmaceutical entity focused on the development and commercialization of therapeutic interventions designed to prevent and treat infectious diseases within the United States market. The company currently offers Arakoda, a specific therapy formulated for malaria preventative treatment, serving as its primary commercial offering in the infectious disease space. Operating within the broader Healthcare sector and the specific Biotechnology industry, the company functions as an emerging player seeking to address critical public health needs through innovative drug candidates. The enterprise operates with a highly lean structure, employing only three individuals to drive its research and development initiatives. With a total market capitalization of $4.77M and annual revenue of $1.41M, the company occupies a very small niche in the capital markets. These valuation figures indicate that the firm is in an early-stage development phase where market cap is significantly lower than mature peers, reflecting its pre-revenue or low-revenue status. The minimal revenue base combined with a tiny workforce suggests the business is currently reliant on external financing to fund its product pipeline rather than generating substantial commercial cash flows.
वित्तीय स्वास्थ्य
The company reported revenue of $1.41M over the trailing twelve months, yet recorded a net income of $-7,866,214, highlighting a substantial disparity between top-line sales and bottom-line profitability. This significant gap reveals a cost structure dominated by high operating expenses, likely associated with clinical trials, regulatory filings, and specialized research activities that outweigh current sales generation. The firm generated EBITDA of $-7,675,707, further underscoring the heavy burn rate typical of biotechnology firms in the discovery and development phases. Free cash flow stood at $-4,493,533, indicating that the company is consuming cash reserves to fund operations and R&D rather than generating surplus liquidity for dividends or share buybacks. The balance sheet presents a mixed picture of liquidity and leverage, holding $2.75M in cash against $152,775 in debt, resulting in a debt-to-equity ratio of 4.52 which technically classifies the entity as highly leveraged relative to its equity base. Despite the high debt-to-equity figure, the current ratio of 2.66 suggests adequate short-term liquidity to meet obligations as they come due. Profitability metrics are severely challenged, with a gross margin of 44.5%, an operating margin of -606.0%, and a profit margin of 0.0%, illustrating that current operations are not yet self-sustaining. Return on equity is -200.9% and return on assets is -87.2%, metrics that indicate management is currently destroying shareholder value through losses rather than creating returns.
मूल्यांकन आकलन
Valuation multiples for the company are distorted by its lack of profitability, showing a P/E ratio (TTM) of N/A and a forward P/E of -0.23. The negative forward P/E implies that the market is pricing in a return to profitability or significant cost reduction in the near term, although current earnings do not support a traditional multiple. The price-to-book ratio stands at -0.34, a negative figure indicating that the market values the company below its book value, often seen in distressed or pre-profitable biotech firms where intangible assets are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 3.39 and an EV/EBITDA of -1.52 suggest the market is willing to pay a premium for the potential of its drug pipeline rather than current earnings power. The stock has exhibited extreme volatility over the past year, trading between a 52-week low of $1.29 and a high of $17.68. Based on the available data points, the current price sits significantly below the 52-week high, reflecting the uncertainty surrounding the company's path to commercial success. The beta of 3.28 indicates that the stock is more than three times as volatile as the broader market, exposing investors to substantial price swings relative to general market movements.
Growth & Income
Revenue growth year-over-year is reported at 16.2%, demonstrating an ability to expand sales despite the early stage of the business, while earnings growth is N/A due to persistent losses. The absence of earnings growth data compared to positive revenue growth implies that the company is prioritizing market expansion and pipeline development over immediate profit generation. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available resources are being reinvested into research, development, and commercialization efforts rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by high revenue expansion coupled with significant losses and no current income distribution, typical of early-stage biotechnology enterprises. The 16.2% revenue increase suggests some traction in commercializing Arakoda, though the financial health metrics indicate that significant capital is still required to achieve sustainable operations.